CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 150 enrolled
Drug / intervention
VIS410 low dose +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02989194
NCT02989194Phase 2Completed
CompareCT.gov

A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of an Investigational Monoclonal Antibody With Code Name VIS410 in Subjects With Uncomplicated Influenza A Infection

Visterra, Inc.·interventional·Posted Dec 12, 2016·Updated Aug 15, 2022

In Brief

A Phase 2 clinical trial evaluating VIS410 low dose, VIS410 high dose, and 1 other intervention for Influenza. Completed, enrolled 150 participants across 54 sites in 7 countries.

Detailed Summary

This is a Phase 2a randomized, double-blind, placebo-controlled study designed to assess the safety and tolerability of an investigational monoclonal antibody, VIS410, in subjects with uncomplicated influenza.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesBulgaria, Estonia, Latvia, Serbia, South Africa, Ukraine, United States
CollaboratorsBiomedical Advanced Research and Development Authority

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 12, 2016
Enrollment StartJan 6, 2017
Primary CompletionOct 27, 2017
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 9.6 years ago

Interventions

VIS410 low dosedrug

Single intravenous fixed low dose of VIS410

VIS410 high dosedrug

Single intravenous fixed high dose of VIS410

Placebodrug

Single intravenous infusion of placebo